148583-69-1

Basic information

• Product Name: 3-Bromomethylbenzenesulfonyl chloride
• Synonyms: 3-Bromomethylbenzenesulfonyl chloride;3-(broMoMethyl)benzene-1-sulfonyl chloride
• CAS NO: 148583-69-1
• Molecular Formula: C₇H₆BrClO₂S
• Molecular Weight: 269.545
• Mol File: 148583-69-1.mol

Chemical Properties

• Boiling Point: 343.445 °C at 760 mmHg
• Flash Point: 161.51 °C
• Appearance: /
• Density: 1.732
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.593
• CAS DataBase Reference: 3-Bromomethylbenzenesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromomethylbenzenesulfonyl chloride(148583-69-1)
• EPA Substance Registry System: 3-Bromomethylbenzenesulfonyl chloride(148583-69-1)

Safety Data

• Hazardous Substances Data: 148583-69-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromomethylbenzenesulfonyl chloride is used as a synthetic intermediate for the development of various pharmaceuticals. Its reactivity allows for the creation of a wide range of sulfonyl compounds, which are essential in the synthesis of drugs with diverse therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromomethylbenzenesulfonyl chloride is utilized as a key component in the synthesis of agrochemicals. Its ability to form sulfonyl compounds contributes to the development of effective pesticides and other agricultural chemicals that protect crops and enhance yield.
Used in Dye Industry:
3-Bromomethylbenzenesulfonyl chloride is employed as a chemical intermediate in the production of dyes. Its involvement in the synthesis process leads to the creation of a variety of dyes used in different industries, including textiles, plastics, and printing inks.
Used in Organic Chemistry Research:
3-Bromomethylbenzenesulfonyl chloride is used as a research tool in organic chemistry. Its reactivity with nucleophiles makes it an important compound for studying reaction mechanisms and developing new synthetic methods.
Safety Precautions:
Due to the hazardous nature of 3-Bromomethylbenzenesulfonyl chloride, it is crucial to follow proper safety protocols when handling this compound. This includes wearing appropriate personal protective equipment, working in a well-ventilated area, and adhering to strict laboratory safety guidelines to minimize the risk of exposure and potential health hazards.

InChI:InChI=1/C7H6BrClO2S/c8-5-6-2-1-3-7(4-6)12(9,10)11/h1-4H,5H2

Upstream product

• 1899-93-0 3-methylphenylsulfonyl chloride 
• 128-08-5 N-Bromosuccinimide 

Downstream Products

• 866787-69-1 1-(3-bromomethyl-benzenesulfonyl)-4-(4-trifluoromethyl-phenyl)-piperazine 
• 148582-97-2 1-[3-[[4[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]phenyl sulfonyl]-4-hydroxypiperidine 
• 1227160-36-2 1-{[3-(bromomethyl)phenyl]sulfonyl}-4-methylpiperazine 
• 148583-70-4 1-{[3-(bromomethyl)phenyl]sulfonyl}-4-hydroxypiperidine 
• 1227159-64-9 1-({3-[(5-methyl-3-{3-[4-(1,1,1-trifluoro-2-methylpropan-2-yl)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)methyl]phenyl}sulfonyl)piperidin-4-ol 
• 91-98-5 n-ethyl-n-benzyl-3-sulfo-m-methylaniline 

Relevant articles and documents

METHOD FOR PRODUCING ETHYL ANILINO TOLUENE SULFONIC ACID DERIVATIVE

To provide a method for producing an ethyl anilino toluene sulfonic acid derivative or a salt thereof, which is an intermediate for obtaining BBG or the like.SOLUTION: The present invention relates to a production method based on the following scheme.SELECTED DRAWING: None

HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS

The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention

ANTIVIRAL COMPOUNDS AND USE THEREOF

The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.

N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof

The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds, compositions comprising an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactiv

4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY

The present invention relates to 4-phenyl-5-oxo-l,4)5,6,7,8-hexahydroquinoline derivatives according to Formula I, Formula I or a pharmaceutically acceptable salt thereof, wherein R1 is (l-6C)alkyl, (2-6C)alkenyl or (2-6C)aDcynyl; R2, R3 are independently halogen, (l-4C)allcyl, (2-4C)alkenyl, (2-4C)- alkynyl, (1 -4C)aBcoxy, (3-4C)alkenyloxy or (3-4C)alkynyloxy; R4 is phenyl or (2-5C)- heteroaryl, both substituted with R7 and optionally substituted on the (hetero)aromatic ring with one or more substituents selected from hydroxy, amino, halogen, nitro, trifluoromethyl, cyano, (l-4C)alkyl, (l-4C)alkoxy , (l-4C)alkylthio and (di)(l-4C)- alkylamino. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 4-phenyl-5-oxo-l, 4,5,6, 7,8-hexahydro- quinoline derivatives in therapy, more specifically for the treatment of infertility

Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders

Aryl sulfonamide and sulfonyl compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT(1A), and adrenergic α1 receptors

New antipsychotic drugs are needed because current therapy is ineffective for many schizophrenics and because treatment is often accompanied by extrapyramidal symptoms and dyskinesias. This paper describes the design, synthesis, and evaluation of a series of related (aminomethyl)benzamides in assays predictive of antipsychotic activity in humans. These compounds had notable affinity for dopamine D2, serotonin 5- HT(1A), and α1-adrenergic receptors. The arylpiperazine 1-[3-[[4-[2-(1- methylethoxy)phenyl]-1-piperazinyl]methyl]benzoyl]piperidine (mazapertine, 6) was chosen because of its overall profile for evaluation in human clinical trials. The corresponding 4-arylpiperidine derivative 67 was also highly active indicating that the aniline nitrogen of 6 is not required for activity. Other particularly active structures include homopiperidine amide 14 and N-methylcyclohexylamide 31.

4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES

Compounds of the general formula I: STR1 are disclosed as novel antipsychotic agents.